Posts

A Banner Month: October 2026 Brings a New Approval, Four Practice-Shaping Phase 3 Trials, and a Rewritten Radiation Guideline

Image
Informed Prostate Cancer Support Group Newsletter Special Report · November 2026 · Covering developments of October 2026 A Banner Month: October 2026 Brings a New Approval, Four Practice-Shaping Phase 3 Trials, and a Rewritten Radiation Guideline From Madrid to Washington, the past month delivered progress for men at nearly every stage of the disease — from the biopsy decision to heavily pretreated metastatic cancer. Here is what happened, what the numbers actually say, and what remains unproven. IPCSG Newsletter · Research Roundup · Sources current through November 2, 2026 Every autumn the European Society for Medical Oncology (ESMO) Congress produces a crop of prostate cancer news, but October 2026 was unusually rich. The 2026 congress, held in Madrid from October 23 to 27, featured a prostate cancer trial in its Presidential Symposium, three further practice-relevant phase 3 updates, and first-in-human data on several genuinely new classes of drugs. [10,11,12] On Octob...
Post a Comment
Read more

When Surveillance Turns to Surgery: What a Norwegian Study of 7,600 Men Tells Us

Image
Surveillance Before Prostatectomy Tied to Adverse Pathology Men who had surgery after a period of active surveillance had more advanced disease in the removed prostate, but their ten-year survival was the same. The lesson is about how surveillance is done, not whether to do it. Stephen L. Pendergast, IPCSG  |  September 2026 Bottom Line Up Front A nationwide Norwegian registry study published September 19, 2026 in the World Journal of Urology compared 1,839 men who had their prostate removed after a period of active surveillance with 5,767 similar men who had surgery right away. The surveillance-then-surgery group had about twice the odds of "adverse pathology" (cancer that was higher grade or had grown beyond the prostate) and a roughly 50% higher adjusted chance of needing radiation or hormone therapy after surgery. 1 The reassuring part: ten-year prostate cancer survival did not differ between the two groups, and three out of four men on surveillance never we...
Post a Comment
Read more

What the July 2026 FDA Expansion Means for Men with Advanced Prostate Cancer

Image
Sharp Memorial offers new treatment for advanced prostate cancer – NBC 7 San Diego Pluvicto Moves Earlier:  A San Diego Navy veteran's story, the research behind the headlines, and the questions to bring to your next oncology visit. By Stephen L. Pendergast, IPCSG  |  September 2026 (Prostate Cancer Awareness Month) Bottom Line Up Front On July 31, 2026, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), given together with a modern hormone pill (an ARPI), for men whose PSMA-positive prostate cancer has spread but still responds to hormone therapy . Until now, Pluvicto was limited to men whose cancer had stopped responding to hormones. Novartis says the change nearly doubles the number of eligible men. The approval rests on the PSMAddition trial of 1,144 men. Adding Pluvicto to standard hormone therapy lowered the risk of cancer progression or death by 28% at the primary analysis and by 33% at an updated analysis. A survival advantage is trending in ...
Post a Comment
Read more

Momentum in Advanced Prostate Cancer: What the Last Month Delivered for Men Living with Metastatic Disease

Image
Special Report:  Informed Prostate Cancer Support Group  •  San Diego, California IPCSG Member Newsletter  •  Research & Treatment Update September 2026  •  Educational Use Only For men living with metastatic castration-resistant prostate cancer (mCRPC) and their families, the weeks from mid-August through mid-September 2026 brought a steady drumbeat of encouraging news. Radioligand therapy continued its march across every stage of metastatic disease, a new generation of immune-based "T-cell engagers" moved deeper into late-stage testing, precision medicine pressed earlier into the disease course, and a landmark government action promised real relief on the price of one of our most-used pills. This report gathers those developments in one place, with an eye toward what they mean for men whose disease no longer responds to hormone therapy alone. 1. Radioligand therapy: now a tool for every stage The biggest story of t...
Post a Comment
Read more